Scholarlink

Background <p>Precision of clinical diagnosis in neurodegenerative diseases is critically important for clinical care and study recruitment. This study aimed to investigate the clinical accuracy using gold-standard neuropathological reference.</p> Methods <p>Neuropathological diagnoses from the Neurobiobank München were correlated with real-world clinical diagnoses from hospitals in Germany. Accuracy metrics, including sensitivity, specificity, and area under the curve (AUC) of clinical diagnoses, were calculated.</p> Results <p>Among nine neuropathologically diagnosed neurodegenerative diseases (Alzheimer’s disease, argyrophilic grain disease, corticobasal degeneration, frontotemporal lobar degeneration, Huntington’s disease, Lewy body disease, motor neuron disease, multiple system atrophy, and progressive supranuclear palsy) with a total of 455 cases, clinical sensitivity varied widely (0–100%) whereas specificity was consistently high (89.5–100%). Accuracy was very good (AUC &gt; 0.9) for Huntington’s disease, motor neuron disease, and multiple system atrophy; good (AUC = 0.8–0.9) for Alzheimer’s disease, dementia with Lewy bodies/Parkinson’s disease, and progressive supranuclear palsy; moderate (AUC = 0.7–0.8) for frontotemporal dementia, limited (AUC = 0.51–0.7) in the <i>n</i> = 20 cases with corticobasal degeneration, and no discriminatory capacity (AUC = 0.5) in the <i>n</i> = 6 cases with argyrophilic grain disease.</p> Conclusions <p>Clinical diagnostic accuracy of neurodegenerative diseases varies, with sensitivity as the main limiting factor. Improving diagnostic sensitivity will be essential for early and accurate patient identification, especially as disease-modifying therapies targeting causal proteinopathies become available. Achieving this will depend on the development and clinical implementation of reliable molecular biomarkers that indicate the causal proteinopathies of neurodegenerative diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Accuracy of clinical diagnosis in neurodegenerative diseases - a study of 455 autopsy cases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月20日

查看全文
  • Jonathan Vöglein,
  • Thomas Arzberger,
  • Irena Ebner,
  • Jochen Herms,
  • Sigrun Roeber,
  • Viktoria Ruf,
  • Adrian Danek,
  • Armin Giese,
  • Günter U. Höglinger,
  • Johannes Levin

摘要

Background

Precision of clinical diagnosis in neurodegenerative diseases is critically important for clinical care and study recruitment. This study aimed to investigate the clinical accuracy using gold-standard neuropathological reference.

Methods

Neuropathological diagnoses from the Neurobiobank München were correlated with real-world clinical diagnoses from hospitals in Germany. Accuracy metrics, including sensitivity, specificity, and area under the curve (AUC) of clinical diagnoses, were calculated.

Results

Among nine neuropathologically diagnosed neurodegenerative diseases (Alzheimer’s disease, argyrophilic grain disease, corticobasal degeneration, frontotemporal lobar degeneration, Huntington’s disease, Lewy body disease, motor neuron disease, multiple system atrophy, and progressive supranuclear palsy) with a total of 455 cases, clinical sensitivity varied widely (0–100%) whereas specificity was consistently high (89.5–100%). Accuracy was very good (AUC > 0.9) for Huntington’s disease, motor neuron disease, and multiple system atrophy; good (AUC = 0.8–0.9) for Alzheimer’s disease, dementia with Lewy bodies/Parkinson’s disease, and progressive supranuclear palsy; moderate (AUC = 0.7–0.8) for frontotemporal dementia, limited (AUC = 0.51–0.7) in the n = 20 cases with corticobasal degeneration, and no discriminatory capacity (AUC = 0.5) in the n = 6 cases with argyrophilic grain disease.

Conclusions

Clinical diagnostic accuracy of neurodegenerative diseases varies, with sensitivity as the main limiting factor. Improving diagnostic sensitivity will be essential for early and accurate patient identification, especially as disease-modifying therapies targeting causal proteinopathies become available. Achieving this will depend on the development and clinical implementation of reliable molecular biomarkers that indicate the causal proteinopathies of neurodegenerative diseases.